Digital Pathology Podcast

Aleksandra Zuraw, DVM, PhD

Aleksandra Zuraw from Digital Pathology Place discusses digital pathology from the basic concepts to the newest developments, including image analysis and artificial intelligence. She reviews scientific literature and together with her guests discusses the current industry and research digital pathology trends.

  1. 25 APR

    236: Quality, Teaching, and AI: A Practical Shift in Pathology

    Send us Fan Mail Where is AI in pathology actually becoming useful right now? In this episode of DigiPath Digest, I review 4 new PubMed papers across digital pathology, whole slide imaging (WSI), computational pathology, medical education, forensic pathology, and breast cancer AI. We look at a deep learning tool for coronary artery stenosis measurement in forensic autopsies, an AI-powered digital pathology model for renal pathology education, an open-source quality control tool for prostate biopsy whole slide images, and a breast cancer stage prediction model built for resource-constrained settings using low-magnification H&E slides. I also share updates on the upcoming second edition of Digital Pathology 101 and the decision to make AI paper summaries public on the podcast feed to help busy pathology professionals stay current.  Highlights   [01:28] Update on the upcoming second edition of Digital Pathology 101 and the release of public AI paper summaries for faster literature review. [05:22] Paper 1: Deep learning for coronary artery stenosis evaluation in forensic autopsies using whole slide imaging. Why objective stenosis measurement matters, how the model outperformed visual estimates, and why this could affect adoption in forensic pathology. [15:18] Paper 2: AI-powered digital pathology with case-based teaching in renal education. A practical discussion on annotated digital slides, flipped classroom learning, and how digital pathology can improve pathology education and diagnostic reasoning. [21:34] Paper 3: Open-source AI for quantitative quality control in prostate biopsy whole slide images. Why WSI quality control matters, what PathProfiler measures, and how automated QC can support remote pathology workflows. [32:38] Paper 4: Breast cancer stage prediction from H&E whole slide images in resource-constrained settings. A look at low-magnification AI, vision transformers, and what moderate performance can still mean when access to advanced testing is limited. [45:06] Closing thoughts, invitation to vote for future AI paper summaries, and a final reminder to download Digital Pathology 101.  Resources Paper 1: Development of a deep learning-based tool for coronary artery stenosis evaluation in forensic autopsies using whole slide imaging PubMed: https://pubmed.ncbi.nlm.nih.gov/41998396/ Paper 2: Integrating AI-Powered Digital Pathology With Case-Based Teaching: A Novel Paradigm for Renal Education in Medical School PubMed: https://pubmed.ncbi.nlm.nih.gov/41995002/ Paper 3: Application of an open-source AI tool for quantitative quality control in whole slide images of prostate needle core biopsies - a retrospective study PubMed: https://pubmed.ncbi.nlm.nih.gov/41994924/ Paper 4: Deep-learning-based breast cancer stage prediction from H&E-stained whole-slide images in resource-constrained settings PubMed: https://pubmed.ncbi.nlm.nih.gov/41993946/ Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    36 min
  2. 231: The Future of Bone Marrow Biopsy: Omics and AI Integration

    20 APR

    231: The Future of Bone Marrow Biopsy: Omics and AI Integration

    Send us Fan Mail Paper Discussed in this Episode: Advancements in bone marrow biopsy: the role of omics and artificial intelligence in hematologic diagnostics. Maryam Alwahaibi and Nasar Alwahaibi. Front. Med. 2026; 13:1772478. Episode Summary: In this journal club deep dive, we explore a paradigm shift in hematopathology, moving from 19th-century visual assessments to the cutting edge of precision medicine. We examine a 2026 review that unpacks how combining artificial intelligence with multi-omics technologies is transforming the traditional bone marrow biopsy from a static, subjective snapshot into a live, interactive, predictive 3D map. We ask: What happens when deep learning can predict underlying genetic mutations just by analyzing the visual shape and texture of a cell?. In This Episode, We Cover: The Breaking Point of Traditional Diagnostics: Why the 150-year-old gold standard of H&E staining and human visual assessment is hitting a biological and operational wall, plagued by subjectivity, high variability, and observer fatigue. The Multi-Omics Multiverse: Moving beyond standard genomics to unpack the complex biological machinery of the marrow, including: Epigenomics: The biological "switches," like DNA methylation, that control cell fate and can kick off malignant transformation without altering the underlying DNA sequence. Lipidomics: How cellular fats form specialized signaling rafts that actively remodel the marrow's communication network. Microbiomics (The Gut-Marrow Axis): How systemic inflammation driven by gut dysbiosis acts like a massive "traffic jam" that indirectly disrupts local bone marrow homeostasis and blood cell production. AI as the Ultimate Analytical Partner: How artificial intelligence serves as a bridge between physical tissue morphology and high-dimensional molecular data. We discuss AI tools like MarrowQuant for objective cellularity mapping and the Continuous Index of Fibrosis (CIF) that replaces clunky human guesswork with a granular, predictive metric. Predicting Genotype from Phenotype: The revolutionary capability of deep learning models to predict underlying genetic mutations (like TET2 or del 5q MDS) purely from the subvisual, spatial arrangement and shape of cells on a standard slide. Roadblocks and Solutions: Why this technology isn't universally adopted yet. We break down the "black box" problem of AI, the brittleness of algorithms in different clinical settings, and how innovations like Federated Learning and Explainable AI (using heat maps) are overcoming these hurdles. Key Takeaway: The integration of AI and multi-omics is redefining our understanding of bone marrow diseases. By uncovering invisible molecular machinery and objectively translating it through transparent algorithms, we are moving away from subjective human bottlenecks toward a highly personalized, predictive model of hematologic care. Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    21 min
  3. 230: Artificial Intelligence in Clinical Oncology: Multimodal Integration and Translational Development

    20 APR

    230: Artificial Intelligence in Clinical Oncology: Multimodal Integration and Translational Development

    Send us Fan Mail Paper Discussed in this Episode: Artificial intelligence in clinical oncology: Multimodal integration and translational development. Ruichong Lin, Zhenhui Zhao, Zhonghai Liu, Jin Kang, Kang Zhang, Xiaoying Huang, Yunfang Yu. Cancer Letters 2026; Volume 649, 218493. Episode Summary: In this journal club deep dive, we explore how cutting-edge AI is fundamentally rewriting the rules of cancer diagnostics. We examine a comprehensive 2026 review on clinical oncology that highlights the shift from narrow, single-modality algorithms to highly sophisticated multimodal AI. We discuss how machines are learning to cross-reference patient charts, genomic data, and medical imaging simultaneously to achieve unprecedented feats—like accurately predicting tumor mutations without ever performing a physical biopsy. Plus, we explore the controversial but necessary world of "computational hallucinations" or synthetic data, which is currently being used to solve diagnostic blind spots. In This Episode, We Cover: • The Fragmentation Bottleneck: Why keeping radiology, pathology, genomics, and clinical history in isolated silos limits our ability to treat the whole patient, and why single-modality AI suffers from severe diagnostic "tunnel vision". • Cross-Modal Attention & Non-Invasive Biopsies: How models like LUCID essentially mimic the deductive reasoning of a multidisciplinary tumor board. By utilizing cross-modal attention mechanisms, LUCID dynamically shifts focus between CT scans, routine labs, and text-based clinical charts to predict EGFR gene mutations in lung cancer entirely non-invasively. • Graph Neural Networks (GNNs) & Tumor Social Networks: A look at the NePSTA framework, which uses GNNs and spatial transcriptomics to treat the tumor microenvironment like a mathematical topology. By mapping the "social network" of cells, it can rapidly molecularly subtype notoriously ambiguous central nervous system (CNS) tumors in minutes. • Computational Hallucinations: Introducing MINIM, a generative AI foundation model that creates statistically valid, photorealistic synthetic medical images (like optical CT or chest X-rays) for rare diseases based on textual descriptions. We discuss how intentionally generating these synthesized images solves the critical "data scarcity" problem and directly improves real-world diagnostic accuracy. • The Reality Check - Distribution Shifts: The dangerous logistical reason why an AI model boasting near-perfect accuracy at a massive urban academic center might fail completely in a rural clinic due to differing scanner calibrations and population demographics. We emphasize why the field must transition away from retrospective "vanity metrics" and toward clinically trustworthy prospective validation. • The Virtual Cell Paradigm: A staggering look into the near future where AI constructs completely accurate, computationally interactive digital twins of a patient's cancer. This framework allows doctors to test different drug regimens and simulate cellular responses mathematically in silico before ever administering medicine to the actual patient. Key Takeaway: Multimodal AI proves that cancer diagnostics must go beyond isolated data points. By dynamically synthesizing highly fragmented clinical information and utilizing synthetic imaging to overcome rare disease data scarcity, AI is pushing oncology into an era of robust, individualized molecular phenotyping. Ultimately, these innovations are replacing risky, invasive testing with prec Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    21 min
  4. 229: Spatial Omics and AI for Clinically Actionable Cancer Biomarkers

    20 APR ·  BONUS

    229: Spatial Omics and AI for Clinically Actionable Cancer Biomarkers

    Send us Fan Mail Paper Discussed in this Episode: Spatial omics and AI for clinically actionable cancer biomarkers. Reitsam NG. PLoS Med 2026; 23(4): e1005049. Episode Summary: In this deep dive, we explore how artificial intelligence and spatial omics are fundamentally rewriting the rules of cancer diagnostics. We break down a 2026 editorial that challenges a deceptively simple question driving modern oncology: Is a tumor "positive" or "negative" for a biomarker? As targeted cancer therapies evolve, this binary thinking is failing us. We discuss why mapping where and how much of a therapeutic target exists is crucial, and how AI is stepping in to solve the reproducibility issues human pathologists face when making borderline diagnostic calls. In This Episode, We Cover: • The Illusion of "Positive" vs. "Negative": Why the basic premise of modern cancer therapies—like antibody-drug conjugates (ADCs)—often falls apart in reality when we ignore the spatial heterogeneity of a tumor. • The Power of Computational Pathology: How AI is transforming subjective, qualitative estimates into continuous, reproducible data, scaling the quantification of complex biomarkers like PD-L1 and TROP2. • "Virtual" Proteomics: The fascinating concept of using AI models to infer high-dimensional spatial information and immune maps directly from standard, routine H&E stained slides. • The HER2 Bottleneck: A real-world look at the breast cancer drug T-DXd, which now demands pathologists distinguish between "HER2-low" and "HER2-ultralow". While human agreement drops below 70% at these fuzzy decision boundaries, AI steps up with a staggering ~97% sensitivity. • Three Shifts for the Future: Why clinical trials and routines must adopt continuous measures (like percentage of expressing cells), demand longitudinal repeat testing at disease progression, and utilize adaptive trial platforms. • Bridging the Gap to Reality: The massive hurdles preventing widespread adoption—such as equipment costs exceeding $250,000 and massive data storage needs. We discuss why a hybrid workflow that bolsters routine pathology with deployable AI is the best path forward to prevent widening global health disparities. Key Takeaway: The future of precision oncology isn't just about finding new drug targets; it’s about fundamentally changing how we measure them. By moving away from rigid binary thresholds and using AI to map the continuous, spatial reality of tumors, we can unlock the true potential of targeted therapies. However, achieving this diagnostic ecosystem requires overcoming significant financial and systemic hurdles—such as updating reimbursement pathways and proficiency testing—to ensure these life-saving insights are accessible across all healthcare settings. Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    23 min
  5. 11 APR

    228: GPT-5 and Gemini 2.5 Pro read pathology slides - here is how they did…

    Send us Fan Mail I did something I've never done before for this episode — I went live from the middle of a national park. This is DigiPath Digest #42, broadcasting from the Great Sand Dunes National Park in Colorado via Starlink from my family road trip. Yes, it actually worked. And so did the papers. This episode covers four papers that all ask the same uncomfortable question from different angles: how close is AI to being genuinely useful in real pathology practice — and what's still standing in the way? From LLMs interpreting cervical Pap smears, to AI guiding breast cancer treatment decisions from a simple H&E slide, to a practical roadmap for bringing generative AI into oncology workflows — this one covers a lot of ground. I also introduced something new: my AI-powered paper summary podcast subscription. For $7 a month, AI hosts summarize digital pathology literature in a journal-club style so you can stay current without spending hours reading abstracts. I walk through how it works and why I built it. What we cover: [00:00] Going live from the wilderness — Starlink, sand dunes, and a very cold morning[02:01] How I use AI-generated audio summaries to prep for each DigiPath Digest[03:19] Paper 1: Can LLMs like ChatGPT and Gemini interpret cervical cytology? Spoiler: ~47–48% exact concordance — promising, but not there yet[10:23] Bonus: My new AI-powered paper summary subscription — $7/month, journal-club style[14:05] Paper 2: AI in oral oncology — CNNs for early lesion detection, multimodal prognostics, and the real barriers still blocking clinical adoption[20:28] Paper 3: Generative AI in oncology — from chat tools to agentic EHR-integrated assistants, and why augmentation is the goal, not automation[25:35] Paper 4: Computational pathology in breast cancer — predicting BRCA1/2, HER2, Oncotype DX, and treatment response from standard H&E slides[31:39] Final thought: the floor just got raised for all of us — how I think about new technology in pathologyResources & Links: Paper 1 – LLMs & Cervical Cytology (PubMed): https://pubmed.ncbi.nlm.nih.gov/41931983/Paper 2 – AI in Oral Oncology (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930554/Paper 3 – Generative AI in Oncology Practice (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930309/Paper 4 – AI & Digital Pathology in Breast Cancer (PubMed): https://pubmed.ncbi.nlm.nih.gov/41930306/Watch on YouTube: https://www.youtube.com/live/O2hOU4gM0Bk?si=oH8iJ8HiBb29USG3Digital Pathology Place: https://www.digitalpathologyplace.comSupport the show Get the "Digital Pathology 101" FREE E-book and join us!

    24 min
  6. 227: Implementing Generative AI and LLM Assistants in Oncology Practice

    10 APR

    227: Implementing Generative AI and LLM Assistants in Oncology Practice

    Send us Fan Mail Paper Discussed in this Episode: How to bring generative AI to oncology practice. D. Truhn & J. N. Kather. ESMO Real World Data and Digital Oncology 2026. Episode Summary: In this journal club deep dive, we step out of the theoretical sci-fi hype of artificial intelligence and look at a practical, real-world roadmap for bringing Generative AI into oncology. We examine a 2026 paper that maps out the trajectory for deploying Large Language Models (LLMs) to combat the overwhelming cognitive load of modern cancer care. Rather than replacing clinicians, this episode explores how AI can synthesize massive amounts of unstructured data—like dense pathology narratives and shifting molecular reports—so doctors can get back to practicing medicine instead of acting as data entry clerks. In This Episode, We Cover: • The Data Avalanche in Oncology: Why the shifting landscape of decades of patient histories, clinical trial registries, and handwritten notes creates an information load that human cognition simply wasn't evolved to process all at once. • How LLMs Actually "Think": Why predicting the "next word" based on massive training data allows AI to mimic medical reasoning and organize complex clinical concepts—like linking a BRAF mutation directly to a specific inhibitor without looking up a rulebook. • The Three Evolutionary Steps of AI Complexity: ◦ Step 1: Stand-alone Models: The "closed-book exam." These models (like early ChatGPT) are frozen in time with their original training data and have zero access to new clinical trials or FDA updates. ◦ Step 2: Retrieval-Augmented Generation (RAG): The "open-book exam." The AI searches continually updated external databases and guidelines before answering, significantly reducing fabricated answers, or "hallucinations". ◦ Step 3: Agentic AI: The ultimate goal. Fully functioning "research assistants" that can iteratively reason, plan steps, and invoke external software tools (like lab APIs and medical calculators) to complete complex tasks like proposing tumor board summaries. • The Deployment Roadblocks: Why you can't just drop an autonomous agent into a fragmented hospital IT network built in 2005. We unpack strict security silos, audit logs, and the dangerous reality of "domain shift"—where an AI trained perfectly at Johns Hopkins might silently fail at a community clinic simply due to different doctor shorthand or microscopic slide scanner colors. • The Human Element & Automation Bias: The hidden dangers of junior doctors losing their clinical intuition (deskilling) and why system design must force the AI to "show its work" with intentional friction to prevent doctors from blindly clicking accept on a hallucinated treatment plan. • Your Edits Are the Future: A fascinating look at how a clinician's daily administrative annoyances—every strike-through and manual correction of an AI draft—serve as the ultimate, high-value ground-truth data to train the next generation of oncology AI. Key Takeaway: The destination we are driving toward is augmentation, not automation. By handling massive information synthesis, uncovering patterns, and explicitly showing its work, AI can act as a tireless assistant that improves routine care, while leaving the final, nuanced clinical judgment exactly where it belongs: with the human physician. Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    23 min
  7. 226: LLM Performance in Cervical Cytology Interpretation: GPT-5 vs. Gemini 2.5

    10 APR

    226: LLM Performance in Cervical Cytology Interpretation: GPT-5 vs. Gemini 2.5

    Send us Fan Mail Paper Discussed in this Episode: Can large language models like ChatGPT and Gemini interpret cervical cytology accurately? Saroja Devi Geetha. Annals of Diagnostic Pathology 2026; Volume 83, 152641. Episode Summary: In this journal club deep dive, we explore what happens when advanced artificial intelligence is thrown into the visually chaotic realm of human biology. We examine a 2026 study evaluating whether two massive multimodal models—GPT-5 and Gemini 2.5 Pro—can accurately read digital cervical Pap smears without any prior fine-tuning,,. We unpack how these general-purpose models perform on highly specialized visual tasks, revealing that while they aren't ready to fly solo, they exhibit fascinating and distinct diagnostic "personalities" that will undoubtedly reshape the future of the pathology lab,. In This Episode, We Cover: • The "Textbook" Test Setup: How researchers tested the baseline visual reasoning of GPT-5 and Gemini 2.5 Pro by feeding them 100 curated, gold-standard digital Pap test images from the Hologic Education Site to classify using the Bethesda System,,. • The Clinical Reality Check: While the models only achieved a coin-toss exact diagnostic match rate (47% for GPT-5 and 48% for Gemini), their accuracy jumped to 66% when evaluating clinical management protocols—proving they are beginning to grasp the underlying severity and medical consequences of cellular abnormalities,,. • The Over-Anxious Resident (Gemini 2.5 Pro): Gemini acted like a highly sensitive but unrefined trainee, hitting 84% sensitivity and expertly spotting infectious organisms (71%),,. However, its tendency to confuse dense, overlapping cellular clumps with high-grade squamous intraepithelial lesions (HSIL) led to massive overcalling, dragging its specificity down to 71% and creating a risk of false alarms,. • The Big-Picture Academic (GPT-5): GPT-5 proved to be much more measured, demonstrating better overall specificity (74%) and excelling at identifying subtle structural shifts like low-grade squamous intraepithelial lesions (LSIL) (75%) and glandular changes,. Yet, in its focus on the big picture, it completely missed obvious infectious organisms, scoring a dismal 20%,. • The Future of the Lab - Prompt Engineering & The Algorithmic Auditor: Why the next era of cytopathology requires rigorous AI fine-tuning on proprietary datasets and cytology-specific prompt optimization. We discuss a major paradigm shift where human pathologists may transition from actively hunting for disease to acting as "algorithmic auditors" whose primary job is to filter out the hyper-vigilant machine's noise,. Key Takeaway: Current multimodal LLMs are not yet reliable for independent Pap test interpretation due to critical blind spots and tendencies to overcall lesions,. However, their out-of-the-box performance establishes a staggering baseline. By understanding their unique mechanical flaws, pathologists can prepare to use these systems as highly effective co-pilots, seamlessly combining the algorithm's computational brute force with the indispensable filter of human medical reasoning Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    24 min
  8. 225: Artificial Intelligence in Oral Oncology: Diagnosis and Therapeutic Integration

    10 APR

    225: Artificial Intelligence in Oral Oncology: Diagnosis and Therapeutic Integration

    Send us Fan Mail Paper Discussed in this Episode: Artificial intelligence in oral oncology: Current advances and future potential in diagnosis, prognosis, and therapeutic decision-making. Annamalai A, Dhanes V, Jayalakshmi L, Shanmugam R, Ravi S. Cancer Treatment and Research Communications 47 (2026) 101193. Episode Summary: In this journal club deep dive, we explore how AI is fundamentally reshaping the clinical management of Oral Squamous Cell Carcinoma (OSCC). We examine a comprehensive March 2026 study that confronts a frustrating paradox: despite the oral cavity being visible to the naked eye, OSCC survival rates have stagnated due to late-stage diagnosis and complex tumor biology. This episode breaks down how algorithms are moving oncology from a reactive discipline to a highly predictive, personalized science. In This Episode, We Cover: • The OSCC Paradox: Why relying on traditional visual inspection and standard TNM staging ignores biological heterogeneity, and how AI steps in where the naked eye and basic anatomy fall short. • Pocket Pathologists: The revolutionary use of Convolutional Neural Networks (CNNs) in smartphone apps and portable devices, achieving up to 82% to 92% sensitivity for point-of-care screening in resource-constrained settings. • The Committee of Algorithms: How AI acts as a "multimodal synthesizer," fusing radiomics (tumor texture), histopathology (tumor-infiltrating lymphocytes), genomics, and Natural Language Processing (NLP) of unstructured clinical notes to predict individualized risk. • Real-Time Margin Guidance: How AI combined with fluorescent imaging provides surgical margin feedback to surgeons in the operating room in under five minutes with over 85% concordance with expert histopathologists. • Digital Twins: The sci-fi reality of running virtual clinical trials. We discuss how AI uses reinforcement learning to build simulated patient copies, allowing tumor boards to predict radiotherapy outcomes and drug toxicities before treating the physical person. • The Black Box, Bias, and the Fix: The major roadblocks preventing immediate clinical rollout. We discuss opaque decision-making and training data bias (which can drop accuracy by over 15% in underrepresented groups). We also explore the solutions: Explainable AI (Grad-CAM heat maps) to visualize decision logic, and Federated Learning (privacy-preserving decentralized training) to eliminate data sharing hurdles. Key Takeaway: The true value of AI in oral oncology isn't in replacing human clinicians, but in digesting massive multi-omics data that no single human could synthesize alone. By acting as a transparent, explainable support tool, AI is setting the stage for a future where tomorrow's healthcare professional might spend as much time treating a virtual patient as the physical one sitting in the chair Support the show Get the "Digital Pathology 101" FREE E-book and join us!

    13 min

About

Aleksandra Zuraw from Digital Pathology Place discusses digital pathology from the basic concepts to the newest developments, including image analysis and artificial intelligence. She reviews scientific literature and together with her guests discusses the current industry and research digital pathology trends.

You Might Also Like